Our team specializing in onco-hematology supports you at every stage of the diagnosis and monitoring of your patients with malignant blood diseases.
Our expert biologists are at your side to advise and guide the examinations to be carried out according to the clinical-biological context of the patient.
At its brand new site in Frépillon, the Cerba laboratory has an innovative technical platform where automation works to improve quality thanks to cutting-edge equipment to manage the volumes involved in these essential analyses. We handle your samples in the cytology, cytometry, cytogenetics and molecular genetics sectors for diagnostic, prognostic and therapeutic purposes.
These rapid tests can be used to put forward or confirm a diagnosis of hematological malignancy, enabling coordination of further investigations.
The myelogram is the first key examination in the diagnostic process for hematological malignancies: after staining bone marrow smears, microscopic study enables qualitative and quantitative analysis of the marrow cells and detection of the presence of abnormal cells.
Immunophenotyping of cells by flow cytometry studies the expression of antigens specific to cells of interest (lymphocytes, blasts, plasma cells and/or monocytes). It specifies the physiological or pathological nature of the cells studied.
A team of highly qualified technicians and biologists carry out and interpret on a daily basis conventional cytogenetics (karyotyping), molecular cytogenetics (FISH) and onco-hematological molecular genetics combining real-time PCR, digital PCR, Sanger sequencing, fragment analyses, high-throughput or next-generation sequencing (NGS), for a complementary and comprehensive analysis offer. Cerba is thus able to carry out cytogenetic and molecular studies of a wide variety of hematological malignancies with validation times allowing optimized, comprehensive patient management.
